|
1
|
Meyers PA, Schwartz CL, Krailo M,
Kleinerman ES, Betcher D, Bernstein ML, et al: Osteosarcoma: a
randomized, prospective trial of the addition of ifosfamide and/or
muramyl tripeptide to cisplatin, doxorubicin, and high-dose
methotrexate. J Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bacci G, Forni C, Longhi A, Ferrari S,
Mercuri M, Bertoni F, et al: Local recurrence and local control of
non-metastatic osteosarcoma of the extremities: a 27-year
experience in a single institution. J Surg Oncol. 96:118–123.
2007.PubMed/NCBI
|
|
3
|
Jawad MU, Cheung MC, Clarke J, Koniaris LG
and Scully SP: Osteosarcoma: improvement in survival limited to
high-grade patients only. J Cancer Res Clin Oncol. 137:597–607.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mialou V, Philip T, Kalifa C, Perol D,
Gentet JC, Marec-Berard P, et al: Metastatic osteosarcoma at
diagnosis: prognostic factors and long-term outcome--the French
pediatric experience. Cancer. 04:1100–1109. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss
J, Szendroi M, et al: Good prognosis of localized osteosarcoma in
young patients treated with limb-salvage surgery and chemotherapy.
Pediatr Blood Cancer. 57:415–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stokkel MP, Linthorst MF, Borm JJ,
Taminiau AH and Pauwels EK: A reassessment of bone scintigraphy and
commonly tested pretreatment biochemical parameters in newly
diagnosed osteosarcoma. J Cancer Res Clin Oncol. 128:393–399. 2002.
View Article : Google Scholar
|
|
7
|
Kuhajda FP: Fatty acid synthase and
cancer: new application of an old pathway. Cancer Res.
66:5977–5980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alo PL, Amini M, Piro F, Pizzuti L,
Sebastiani V, Botti C, et al: Immunohistochemical expression and
prognostic significance of fatty acid synthase in pancreatic
carcinoma. Anticancer Res. 27:2523–2527. 2007.PubMed/NCBI
|
|
9
|
Walter K, Hong SM, Nyhan S, Canto M,
Fedarko N, Klein A, et al: Serum fatty acid synthase as a marker of
pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev.
18:2380–2385. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okawa Y, Hideshima T, Ikeda H, Raje N,
Vallet S, Kiziltepe T, et al: Fatty acid synthase is a novel
therapeutic target in multiple myeloma. Br J Haemato. 141:659–671.
2008. View Article : Google Scholar
|
|
11
|
Migita T, Ruiz S, Fornari A, Fiorentino M,
Priolo C, Zadra G, et al: Fatty acid synthase: a metabolic enzyme
and candidate oncogene in prostate cancer. J Natl Cancer Inst.
101:519–532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Silva SD, Cunha IW, Younes RN, Soares FA,
Kowalski LP and Graner E: ErbB receptors and fatty acid synthase
expression in aggressive head and neck squamous cell carcinomas.
Oral Dis. 16:774–780. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saati GE and Archer MC: Inhibition of
fatty acid synthase and Sp1 expression by 3,3′-diindolylmethane in
human breast cancer cells. Nutr Cancer. 63:790–794. 2011.
|
|
14
|
Notarnicola M, Pisanti S, Tutino V, Bocale
D, Rotelli MT, Gentile A, et al: Effects of olive oil polyphenols
on fatty acid synthase gene expression and activity in human
colorectal cancer cells. Genes Nutr. 6:63–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Notarnicola M, Messa C, Refolo MG, Tutino
V, Miccolis A and Caruso MG: Polyunsaturated fatty acids reduce
fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene
expression and promote apoptosis in HepG2 cell line. Lipids Health
Dis. 10:102011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zecchin KG, Rossato FA, Raposo HF, Melo
DR, Alberici LC, Oliveira HC, et al: Inhibition of fatty acid
synthase in melanoma cells activates the intrinsic pathway of
apoptosis. Lab Invest. 91:232–240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Long XH, Mao JH, Peng AF, Zhou Y, Huang SH
and Liu ZL: Tumor suppressive microRNA-424 inhibits osteosarcoma
cell migration and invasion via targeting fatty acid synthase. Exp
Ther Med. 5:1048–1052. 2013.PubMed/NCBI
|
|
18
|
Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y
and Huang SH: Fatty acid synthase expression in osteosarcoma and
its correlation with pulmonary metastasis. Oncol Lett. 4:878–882.
2012.PubMed/NCBI
|
|
19
|
Liu X, Shi Y, Giranda VL and Luo Y:
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway
sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced
apoptosis. Mol Cancer Ther. 5:494–501. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van de Sande T, De Schrijver E, Heyns W,
Verhoeven G and Swinnen JV: Role of the phosphatidylinositol
3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty
acid synthase in LNCaP prostate cancer cells. Cancer Res.
62:642–646. 2002.
|
|
21
|
Wang HQ, Altomare DA, Skele KL, Poulikakos
PI, Kuhajda FP, Di Cristofano A, et al: Positive feedback
regulation between AKT activation and fatty acid synthase
expression in ovarian carcinoma cells. Oncogene. 24:3574–3582.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Menendez JA and Lupu R: Fatty acid
synthase-catalyzed de novo fatty acid biosynthesis: from
anabolic-energy-storage pathway in normal tissues to
jack-of-all-trades in cancer cells. Arch Immunol Ther Exp (Warsz).
52:414–426. 2004.
|
|
23
|
Menendez JA, Ropero S, Mehmi I, Atlas E,
Colomer R and Lupu R: Overexpression and hyperactivity of breast
cancer-associated fatty acid synthase (oncogenic antigen-519) is
insensitive to normal arachidonic fatty acid-induced suppression in
lipogenic tissues but it is selectively inhibited by tumoricidal
α-linolenic and gamma-linolenic fatty acids: A novel mechanism by
which dietary fat can alter mammary tumorigenesis. Int J Oncol.
24:1369–1383. 2004.PubMed/NCBI
|
|
24
|
Porter D, Lahti-Domenici J, Keshaviah A,
Bae YK, Argani P, Marks J, et al: Molecular markers in ductal
carcinoma in situ of the breast. Mol Cancer Res. 362–375.
2003.PubMed/NCBI
|
|
25
|
Swinnen JV, Vanderhoydonc F, Elgamal AA,
Eelen M, Vercaeren I, Joniau S, et al: Selective activation of the
fatty acid synthesis pathway in human prostate cancer. Int J
Cancer. 88:176–179. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Milgraum LZ, Witters LA, Pasternack GR and
Kuhajda FP: Enzymes of the fatty acid synthesis pathway are highly
expressed in in situ breast carcinoma. Clin Cancer Res.
3:2115–2120. 1997.PubMed/NCBI
|
|
27
|
Yeh CW, Chen WJ, Chiang CT, Lin-Shiau SY
and Lin JK: Suppression of fatty acid synthase in MCF-7 breast
cancer cells by tea and tea polyphenols: a possible mechanism for
their hypolipidemic effects. Pharmacogenomics J. 3:267–276.
2003.PubMed/NCBI
|
|
28
|
Bandyopadhyay S, Pai SK, Watabe M, Gross
SC, Hirota S, Hosobe S, et al: FAS expression inversely correlates
with PTEN level in prostate cancer and a PI 3-kinase inhibitor
synergizes with FAS siRNA to induce apoptosis. Oncogene.
24:5389–5395. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Swinnen JV, Heemers H, Deboel L, Foufelle
F, Heyns W and Verhoeven G: Stimulation of tumor-associated fatty
acid synthase expression by growth factor activation of the sterol
regulatory element-binding protein pathway. Oncogene. 19:5173–81.
2000. View Article : Google Scholar
|
|
30
|
Yang Y, Morin PJ, Han WF, Chen T, Bornman
DM, Gabrielson EW and Pizer ES: Regulation of fatty acid synthase
expression in breast cancer by sterol regulatory element binding
protein-1c. Exp Cell Res. 282:132–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alli PM, Pinn ML, Jaffee EM, McFadden JM
and Kuhajda FP: Fatty acid synthase inhibitors are chemopreventive
for mammary cancer in neu-N transgenic mice. Oncogene. 24:39–46.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Scheid MP, Marignani PA and Woodgett JR:
Multiple phosphoinositide 3-kinase-dependent steps in activation of
protein kinase B. Mol Cell Biol. 22:6247–6260. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li N, Lu H, Chen C, Bu X and Huang P: Loss
of fatty acid synthase inhibits the ‘HER2-PI3K/Akt axis’ activity
and malignant phenotype of Caco-2 cells. Lipids Health Dis.
12:832013.
|
|
34
|
Jin HO, An S, Lee HC, Woo SH, Seo SK, Choe
TB, et al: Hypoxic condition- and high cell density-induced
expression of Redd1 is regulated by activation of hypoxia-inducible
factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt
signaling pathway. Cell Signal. 19:1393–1403. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Roder K, Wolf SS, Larkin KJ and Schweizer
M: Interaction between the two ubiquitously expressed transcription
factors NF-Y and Sp1. Gene. 234:61–69. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Deepa PR, Vandhana S and Krishnakumar S:
Fatty acid synthase inhibition induces differential expression of
genes involved in apoptosis and cell proliferation in ocular cancer
cells. Nutr Cancer. 65:311–316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rahman MT, Nakayama K, Ishikawa M, Rahman
M, Katagiri H, Katagiri A, et al: Fatty acid synthase is a
potential therapeutic target in estrogen receptor-/progesterone
receptor-positive endometrioid endometrial cancer. Oncology.
84:166–173. 2013. View Article : Google Scholar
|
|
38
|
Zhou JD, Shen F, Ji JS, Zheng K, Huang M
and Wu JC: FAM9C plays an anti-apoptotic role through activation of
the PI3K/Akt pathway in human hepatocellular carcinoma. Oncol Rep.
2013. View Article : Google Scholar
|
|
39
|
Yothaisong S, Dokduang H, Techasen A,
Namwat N, Yongvanit P, Bhudhisawasdi V, et al: Increased activation
of PI3K/AKT signaling pathway is associated with cholangiocarcinoma
metastasis and PI3K/mTOR inhibition presents a possible therapeutic
strategy. Tumour Biol. 34:3637–3648. 2013. View Article : Google Scholar : PubMed/NCBI
|
